0001415889-24-009989.txt : 20240403 0001415889-24-009989.hdr.sgml : 20240403 20240403161513 ACCESSION NUMBER: 0001415889-24-009989 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240401 FILED AS OF DATE: 20240403 DATE AS OF CHANGE: 20240403 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: St Leger Tina Amber CENTRAL INDEX KEY: 0001969525 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39992 FILM NUMBER: 24818879 MAIL ADDRESS: STREET 1: C/O IMMUNOCORE LIMITED STREET 2: 92 PARK DRIVE, MILTON PARK, ABINGDON CITY: OXFORDSHIRE STATE: X0 ZIP: OX14 4RY ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Immunocore Holdings plc CENTRAL INDEX KEY: 0001671927 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: X0 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 90 PARK DRIVE STREET 2: MILTON PARK, ABINGDON CITY: OXFORDSHIRE STATE: X0 ZIP: OX14 4RY BUSINESS PHONE: 01235 5430281 MAIL ADDRESS: STREET 1: 90 PARK DRIVE STREET 2: MILTON PARK, ABINGDON CITY: OXFORDSHIRE STATE: X0 ZIP: OX14 4RY FORMER COMPANY: FORMER CONFORMED NAME: Immunocore Ltd DATE OF NAME CHANGE: 20160412 4 1 form4-04032024_040401.xml X0508 4 2024-04-01 0001671927 Immunocore Holdings plc IMCR 0001969525 St Leger Tina Amber C/O IMMUNOCORE HOLDINGS PLC 92 PARK DRIVE, MILTON PARK, ABINGDON OXFORDSHIRE X0 OX14 4RY UNITED KINGDOM false true false false CHIEF HR OFFICER 1 Ordinary Shares 2024-04-01 4 M 0 4375 29.87 A 4375 D Ordinary Shares 2024-04-01 4 S 0 4375 64.06 D 0 D Employee Share Option (Right to Buy) 29.87 2024-04-01 4 M 0 4375 0 D 2032-03-31 Ordinary Shares 4375 35000 D This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 23, 2023. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $63.73 to $64.08 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. 25% of the shares subject to the option award vested on April 1, 2023, and 6.25% of the shares subject to the option award vested or shall vest in quarterly installments thereafter, subject to the Reporting Person's continuous service through each such vesting date. /s/ Lily Hepworth, Attorney-in-Fact 2024-04-03